For research use only. Not for therapeutic Use.
ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].
ALM301 (0.001-10 µM; 72 h) inhibits the proliferation of cancer cells, and PI3KCA-mutant MCF-7 cells is the most sensitive; increases sub-G0 population in a dose-dependent manner[1].
ALM301 (1 µM; 1 h) inhibits AKT phosphorylation in MCF-7 and sustains up to 48 h, with an EC50 value of 0.47 µM[1].
ALM301 (10, 30 and 100 mg/kg; p.o.; single dosage) inhibits pAKTS473 in tumors and suppresses tumor growth[1].
ALM301 (3 or 10 mg/kg; p.o.; q.d. for 49 days) shows better tumor inhibition ability when combined with Tamoxifen (HY-13757A)[1].
| Catalog Number | I042748 |
| CAS Number | 1313439-71-2 |
| Synonyms | 6-[4-(1-amino-3-hydroxycyclobutyl)phenyl]-1-ethyl-7-phenylpyrido[2,3-b][1,4]oxazin-2-one |
| Molecular Formula | C25H25N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H25N3O3/c1-2-28-21-12-20(16-6-4-3-5-7-16)23(27-24(21)31-15-22(28)30)17-8-10-18(11-9-17)25(26)13-19(29)14-25/h3-12,19,29H,2,13-15,26H2,1H3 |
| InChIKey | BPHCAPAOSHZYJY-UHFFFAOYSA-N |
| SMILES | CCN1C(=O)COC2=C1C=C(C(=N2)C3=CC=C(C=C3)C4(CC(C4)O)N)C5=CC=CC=C5 |
| Reference | [1]. Page N, et al. Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development. Sci Rep. 2022 Sep 20;12(1):15715. |
